Compare Hershey Co (HSY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Hershey (HSY) trades at $160.34, down 0.29% on the day, with a bearish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong profitability metrics include a 32.81% ROE and 12.24% net margin, though 2025 net income declined significantly from 2024 levels. Recent corporate developments include new international leadership and ongoing brand investment initiatives.

The stock presents a mixed outlook with 26% upside to the consensus price target of $204.62, but faces headwinds from cocoa cost pressures and technical weakness. While dividend growth has resumed after a nearly two-year freeze, investors should weigh strong brand positioning against commodity volatility and declining institutional holdings in recent quarters.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.